Compare MPLX LP (MPLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs BIO-TECHNE Corp — how do they compare? MPLX LP trades at $57.6 (market cap $58.11B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: MPLX LP is far larger — about 5.1× BIO-TECHNE Corp's market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | TECH | |
|---|---|---|
Market Cap | $58.11B | $11.36B |
Volume | 687,483 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $60.51 | $72.61 |
52-Week Low | $47.80 | $43.31 |
Enterprise Value | $83.22B | $11.39B |
Dividend Yield | 7.51% | 0.44% |
Typical Hold Time | — | 63 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations in Q1 and Q2 2026. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and a resilient midstream business model that limits commodity price exposure.
The outlook is cautiously optimistic given MPLX's fee-based revenue structure and 67.86% buy rating from analysts. Key risks include energy market volatility and potential diesel export restrictions, but the company's distribution coverage ratio of 1.3x supports dividend sustainability. Upside potential exists if Q3 earnings meet or exceed the $1.15 EPS estimate due November 3, 2026.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
